The N-acetyltransferase (NAT) phenotype is an important determinant of individual susceptibility to occupational bladder cancer. N-Acetyltransferases are known to metabolize aromatic amine bladder carcinogens, but the functional significance of NAT expression in the target organ is unclear. To resolve this issue, plydonal antisera against purifed recombinant enzymes and C-terminal peptides of human NAT Type 1 (NAT1) and Type 2 (NAT2) were generated. Western blot analysis of exfoliated cells from human urine, pig bladder homogenate, and human bladder tumor-derived cell lines showed that NATl was expressed in all three systems, whereas NAT2 did not appear to be expressed in the
Introduction
Xenobiotic metabolism is believed to be an important factor in susceptibility to aromatic amine-induced bladder cancer (Smith et al., 1995) . Aromatic amines are metabolized by arylamine N-acetyltransferase (NAT), which catalyzes the transfer of an acetyl group from acetyl CoA to the amine nitrogen of the substrate . In humans, NAT exists in two isoforms with distinct but overlapping specificities. NATl is specific for acetylation ofp-aminobenzoic acid (PABA) and NAT2 catalyzes the acetylation of sulfamethazine (SMZ). Both can acetylate the carcinogen 2-aminofluorene (Grant et al., 1992) . The human NATl and NAT2 isozymes each contain 290 amino acids and are 87% identical at the amino acid level, with most differences occurring in the C-terminal half of the molecule. They are encoded at separate genetic loci, both of which are located on chromosome 8p 21.3-23.1 (Spurr, 1995; Hickman et al., 1994) . Different rates of acetylation are observed among individuals for substrates acetylated by NAT2, and multiple alleles have been found at the corresponding locus (Vatsis et al., 1775; Grant, 1993) . Individuals can be classified as "fast" or "slow" acetylators depending on which alleles they carry at this lo-' Supported by the Wellcome Trust and the Medical Research Council. * Correspondence to: Edith Sim, Dept. of Pharmacology, Univ. of Oxford, Mansfield Road, Oxford OX1 3QT, UK. bladder. Immunohistochemical analysis of human bladder tumor sections indicated that well-differentiated tumor cells expressed NAT1, with the highest level of expression being found in the umbrella cells that line the bladder lumen. b r l y difkentiated tumor regiom appeared to express NATl at lower leveh than did well-differentiated areas. These fmdings support the hypothesis that aromatic amines are metabolized in the bladder epithelium by NAT1. ( J Hisrochem Cyrochem 44: 1059-1067, 19%) cus, and the acetylator type can be determined either by measuring the rate of acetylation of a drug such as isoniazid (Evans et al., 1960) or by polymerase chain reaction (PCR)-based genotyping methods (Vatsis et al., 1995; Hickman, 1992; Hickman and Sim, 1991) . Possession of a single fast (FI) allele is sufficient to confer the fast acetylator phenotype.
Bladder cancer is one of the human neoplastic diseases most strongly linked to exposure to chemical carcinogens. It has been known since 1982 that the NAT phenotype of whites affects their susceptibility to bladder cancer: an excess of slow acetylators is found among those who develop bladder cancer after industrial exposure to arylamines (Risch et al., 1995; Hanek and Krajewska, 1990; Cart-Wright et al., 1782) . More recently, it has been shown that the NAT2 genotype contributes to the bladder cancer susceptibility of smokers as well as industrially exposed subjects (Risch et al., 1995) . However, it is still unclear exactly how the NAT phenotype determines susceptibility. Previous studies of this phenomenon have used phenotyping and genotyping, which determine the overall N-acetylation capacity of the individual, to relate N-acetylation to tumor incidence. The molecular mechanisms involved, however, have not yet been elucidated.
Many approaches, including enzyme activity measurements, mRNA and protein expression studies, and cDNA cloning have shown that NATs 1 and 2 are present in the liver (Deguchi, 1992; Blum et al., 1991; Grant et al., 1990 Grant et al., .1991 Gunawardhana et al., 1991; Ohsako and Deguchi, 1990) . It has been proposed that hepatic NAT detoxifies arylamine carcinogens by N-acetylation but that hepatic cytochrome P4501A2-dependent N-hydroxylation competes with this process (Kadlubar, 1991; Lower, 1982) . The products of P4501A2-dependent activation are believed to accumulate in the bladder, where they are potential substrates for further NATmediated metabolism in the urothelium. It is therefore important to understand expression of NAT in the bladder epithelium to elucidate the pathway of aromatic amine-induced carcinogenesis.
The aim of the present study was to raise polyclonal antisera able to discriminate between human NATs 1 and 2. Two strategies were adopted to achieve this aim. The first involved the generation of polyclonal antisera against purified recombinant NAT proteins and the second was an antipeptide strategy in which antisera were raised against the divergent C-termini of human NATl and NAT2. The antisera generated were used to analyze NAT expression in normal and neoplastic human bladder material using Western blotting and immunohistochemical methods.
Materials and Methods
Chemicals. All chemicals were obtained from UK sources, usually Sigma Chemical Company (Poole, UK) or BDH (Lutterworth, UK) unless otherwise stated.
Expression and Purification of Resumbinant Human NATs 1 and 2. The cloning and expression of NAT using the pGEX-2T (Pharmacia; Milton Keynes, UK) and PET-Sa (Novagen; AMS Biotechnology, Witney, UK) expression systems have been reported previously (Hickman et al., 1995; Ward et al., 1995) . For purification of recombinant proteins, 1-2L cultures of bacteria were harvested, subjected to lysis as described (Ward et al.. 1995) . and desalted by centrifugal ultrafiltration using Centriprep 10 concentrators (Amicon; Stonehouse, UK). Recombinant NAT 1 and NATZ were purified by anion exchange on Q-Sepharose (XK50l60 column; Pharmacia) followed by gel filtration on Superdex 75 (XK26l70 column; Pharmacia) as described previously (Ward et al., 1995) . Fractions were assayed for NATl (PABA acetylation) or NATZ (SMZ acetylation) activity as appropriate (Ward et al., 1992) , and their protein profiles were visualized by SDS-PAGE (Henderson and Wolf, 1992) .
Peptide Synthesis. To generate antisera that could discriminate between NATl and NAT2, the divergent C-termini of NATs 1 and 2 were selected for peptide synthesis. The amino acid sequences used were: NATI: CVPKHGDRFFTI NATZ: CVPKPGDGSLTI A cysteine residue was added at the N-terminus of each peptide to facilitate conjugation to proteins using the heterobifunctional crosslinking reagent Table 1 . Companson of bindinn of antisera t o NATl and NATZ by ELISA sulfoSMCC (sulfosuccinimidyl4-(N-maleimidomethyl) cyclohexane-l-carboxylate) (Pierce and Warriner; Chester, UK). Peptide synthesis was carried out by Dr. Albert Tse at the University of Oxford or by Prof. N.P. Groome at Oxford Brmkes University. The identities of the peptides were confirmed by the producers using amino acid analysis, high-performance liquid chromatography, and/or mass spectrometry.
Preparation of Peptide-Protein Conjugates for Immunization. Ovalbumin or bovine serum albumin (BSA) (10 mg) was dissolved in 900 pl PBS [8 mM NaH2P04, 1.5 mM KH2P04, 0.8% (wlv) NaCI. 0.020h (wlv) KCI, pH 7.51 and reacted with 10 mg sulfoSMCC (added in 900 pl H20) for 1 hr. The activated protein was desalted on Sephadex G25M (PD-10; Pharmacia) and eluted with 0.1 M NaH2P04, pH 6.0. Chilled 0.1 M sodium borohydride (100 pl) was added to S mg peptide in 0.1 M sodium borate, pH 8.0 (150 pl). The mixture was incubated on ice for 5 min, adjusted to pH 1.0, incubated on ice for a further 5 min, returned to pH 7.0. and again incubated on ice for 5 min. The reduced peptide was allowed to react with the activated protein at 4°C for 16 hr. The peptide-protein conjugate was separated from free peptide on a PD-10 column and eluted with PBS. Ten pI from each fraction was analyzed by SDS-PAGE. Fractions in which the protein band had been broadened and shifted to a higher molecular weight by peptide binding were selected for immunization.
Production of Antisera. New Zealand White rabbits (2.5 kg) were immunized intradermally with 0.5-1.0 mg of recombinant protein, peptide-ovalbumin, or peptide-BSA conjugate ( Table 1 ). The first immunization was administered as a 1:1 emulsion with Freund's complete adjuvant and subsequent injections (given at 2-4-week intervals) were prepared in Freund's incomplete adjuvant. After three to five immunizations. when a suitable antibody response had been achieved. blood was removed by cardiac puncture and allowed to clot (1-2 hr at room temperature followed by 16 hr at 4°C). The serum was removed, centrifuged twice in a Sorvall RT 6000D refrigerated benchtop centrifuge (2000 rpm, 4"C, 30 min), and stored at -20°C.
Enzyme-linked Immunosorbent Assay. Flat-bottomed 96-well microtiter plates (Sterilin; Fisons. Lutterworth. UK) were coated with purified recombinant NATl and NAT2 (2 pglwell) and ELISAs were performed essentially as descried by Edwards et al. (1988) , except that the blocking agent used was gelatin (0.1% in PBS + 0.05% Tween 20). Sample Preparation. Exfoliated urothelial cells from healthy female volunteers (all workers in this laboratory who gave informed consent) were prepared according to standard cytological practice (Nguyen and Kline, 1992) . Pig bladder homogenate was prepared by chopping frozen ( -70°C) bladder tissue over solid CO*, resuspending in lysis buffer, and homogenizing with a hand-held teflon-glass homogenizer. Debris was removed by centrifugation in an MSE Microcentaur microcentrifuge (13,000 rpm, 4°C. 10 min). Human tumor-derived cell lines were obtained from the cell bank 0.16 protein from pGEX-2T expression system EC>,, is defined as the effective concentration of antibody (in % v i v ) giving 50% of the maximal absorbance (492 nm) generated after binding of antiserum 177 lo61 of the Sir William Dunn School of Pathology, South Parks Road, Oxford, and were cultured as described previously (Coroneos et al., 1991; Kelly and Sim. 1991) . SDSPAGE and Immunobloning. Electrophoresis (SDS-PAGE) on 12% (wlv) polyacrylamide gels and Western immunoblotting were performed according to established procedures (Henderson and Wolf, 1992) . Nonspecific protein binding sites were blocked with 10% (wlv) dried skimmed milk powder in Tris-buffered saline [TBS 0.05 M Tris HCI, pH 7.9. 0.9% (wlv) NaCI] containing 0.05% (vlv) Tween 20. Subsequent incubations were carried out in 3% (wlv) dried skimmed milk in TBS + 0.05% (vlv) Tween 20. Rabbit antisera were used at a dilution of 1:4000 and horseradish peroxidase-conjugated goat anti-rabbit 1gG was used at a dilution of 1:10,OOO.
Antibody binding was visualized with ECL Western Blotting Detection Reagents (Amenham International; Amenham. UK) according to the manufacturer's instructions.
Immunocytochemical Analysis of Human Bladder Tumors. Slides bearing IO-pm-thick sections of formalin-futed. paraffin-embcdded human bladder tumors were kindly provided by Dr. T. O'Brien (Department of Clinical Oncology, Churchill Hospital. Oxford). Immunocytochemical staining was performed with the Vectastain Elite ABC kit (Vector Labs: Peterborough, UK). Endogenous peroxidase was inhibited with 1% (wlv) HzOz in TBS, sections were incubated with rabbit antiserum at 4'C overnight, and three 10-min TBS washes were performed between each antibody incubation. Rabbit antisera were used at a dilution of 1:lOOO in TBS containing 1.5Oh normal goat serum. After immunostaining, sections were lightly counterstained with Gill's hematoxylin and dehydrated. Coverslips were attached using DPX mountant.
Results

Characterization of Antisera
Antisera raised against recombinant proteins or peptide-protein conjugates were screened by ELISA to select those that bound specifically to either recombinant NATl or NAT2 (Table 1) . Antiserum 177, which was raised against recombinant NATI, recognized both NATl and NAT2. The other antisera (anti-NATI antiserum 184 and anti-NAT2 antisera 094 and 4768) bound only to the relevant antigen on ELISAs. No binding was observed with either antigen when preimmune rabbit serum was used.
The binding characteristics of the antisera were further determined by Western blot analysis using purified recombinant NAT standards (Figure 1 ). Both NATl and NAT2 had apparent molecular weights of 31 KD on SDS-PAGE and Western blot analysis, in .. 8 agreement with previous findings ). The anti-NATl peptide antiserum (184) could detect approximately 3.0 ng of recombinant NATl and did not bind to NATZ under the conditions used (Figures la and 1b ). Antiserum 177 (raised against whole recombinant NAT1) could detect <1.0 ng of recombinant NATl but bound equally well to NATZ ( Figure IC) .
Similar experiments indicated that the antisera raised against NAT2 (094 and 4768) were able to detect NATZ in the range of 10-100 ng. The reason for the lower binding capacity of the NAT2 antisera is unclear. One possibility is that the C-terminal peptide of NATZ is poorly immunogenic. This antiserum, however, is still potentially valuable for the analysis of NATZ expression because it is monospecific, whereas previously reported antisera bind to both NATl and NAT2 (Hein et al., 1994; Blum et al., 1990; Grant et al., 1989) . It is important to bear in mind that when this antiserum is used, a "negative" result implies only "below the level of detection with this antiserum."
NAT Expression in Exfoliated Cells from Healtby Subjects
The expression of NATl was studied by Western blot analysis of exfoliated cells from the urine of healthy female volunteers. The cells analyzed comprised a mixture of transitional epithelial cells from the bladder lining and squamous epithelial cells from the vagina. The number of cells analyzed was 5 x I@, equivalent to approximately 50 vg of total cellular protein. Equivalence of loading was verified using Coomassie Brilliant Blue staining of a duplicate gel (data not shown).
Cells from each of the four urine samples expressed a single 31-KD band consistent with the presence of immunoreactive NATl protein (Figure 2a ). The expression of NATl was not related to NATZ acetylator status, because Individual 1 was a homozygous fast acetylator (FIIFI). Individual 2 was a heterozygote (Fl/S2), and Individuals 3 and 4 were slow acetylators (Sla/Sla and S2/S2, respectively). Biopsy specimens of healthy human bladder were not readily available for this study, so to examine NATl expression in the bladder lining itself, normal pig bladder was analyzed. An immunoreactive band with a molecular weight of 31 KD was detected in pig bladder homogenate (Figure 2a ). This was consistent with the presence in pig bladder homogenate of PABA acetylating capacity (6.69 nmollminlmg protein). 
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At the level of sensitivity achieved in these experiments, NATZ expression was not detectable in exfoliated cells or in normal pig bladder (Figure 2b ). This does not exclude the possibility that NATZ is expressed in these samples but at levels too low to be detected with this antiserum. The amount of protein used was the maximum that could be run on the gel without causing band distortion due to overloading. To confirm this result. the ability of pig bladder to metabolize SMZ was tested. No acetylation of SMZ was detected in incubations of up to 2-hr duration, consistent with the absence of immunoreactive NATZ protein from this tissue.
NAT Expression in Human Bladder Tumor-derived Cell Lines
To determine whether neoplastic as well as normal bladder cells express NAT, Western blot analysis was used to analyze the human bladder tumor-derived cell lines EJ138 and RT112/84. The monocytic cell line U937, which is known to express NATl , was included for comparison. All three cell lines contained immunochemically detectable NATl protein (Figure 3a) . The antiserum used in this analysis (184) was raised against a peptide-BSA conjugate, and the detection of a high molecular weight immunoreactive band in these samples was probably due to incomplete removal of BSA (a component of the cell culture medium used). The level of NATl expressed by EJ138 cells was much lower than that in U937 and RT112/84. This finding is consistent with the results of previous measurements of NATl activity in these cell lines, which showed that the rate of PABA acetylation by EJ138 cytosol was considerably slower than that of RTl12184 or U937 cytosol (0.853, 3.698, and 2.460 nmollminlmg protein, respectively) (Coroneos and Sim, 1991) .
As with normal bladder tissue, NAT2 protein was undetectable in human tumor-derived cell lines under the conditions used (Figure 3b ). As mentioned above, this does not exclude the possibility that NATZ was present at levels too low for detection by this antiserum. The absence of NAT2 protein from the human tumor-derived cell lines, is, however, consistent with their inability to metabolize SMZ, as reported previously (Coroneos and Sim, 1991) .
Immunocytochemical Localization of NATl in Bladder Tumors
The distribution of NATl was examined in neoplastic bladder by immunocytochemistry using antiserum 184 (anti-NAT1 C-terminal peptide). The tumors analyzed were transitional cell carcinomas of the bladder that contained a mixture of well-differentiated (papillary) and poorly differentiated (solid) areas. Antiserum 184 stained tumor cell cytoplasm in these samples (Figure 4) . Well-differentiated areas that still exhibited some morphological characteristics of normal bladder epithelium stained intensely, whereas less welldifferentiated regions stained only faintly (Figures 4a and 4b) . No staining was observed when preimmune rabbit serum was used instead of antiserum 194 (Figure 4c ). At higher magnification ( x 400), the most intense staining was present in the umbrella cells that line the bladder lumen, whereas the basal epithelial cells exhibited more moderate staining (Figure 4d ).
Discussion
This report describes the generation of antisera against human NAT isozymes 1 and 2 using both recombinant proteins and the antipeptide approach. Use of the anti-peptide strategy facilitated the production of highly specific polyclonal antisera against both NATl and NAT2. The antiserum raised against the NATl C-terminus recognized NATl but not NAT2 on ELISAs and Western blots; that raised against the C-terminus of NAT2 had the reverse pattern of specificity. Similar success has recently been reported in generating highly specific antisera against cytochrome P450s, another family of proteins in which the members are highly homologous at the amino acid level (Edwards et al., 1995) .
With these anti-peptide antisera, the expression of NATl and NATZ in human bladder was characterized by Western blot analysis and immunocytochemistry. NATl was detected in normal bladder epithelial cells by Western blotting and immunocytochemical analysis. Exfoliated cells from the urine of four healthy female individuals were analyzed and NATl was present in cells from all four individuals, confirming the results of preliminary studies in which we detected NATl immunocytochemically in exfoliated cells (Cuff et al., 1996) . These findings are consistent with previous reports of NAT activity in normal human bladder (Frederickson et al., 1992 (Frederickson et al., ,1994 Kirlin et al., 1989; Land et al., 1989) . Human bladder cytosol has previously been shown to contain N-acetylating capacity towards PABA as well as towards bladder carcinogens including 4-aminobiphenyl, 2-aminofluorene, and B-naphthylamine (Frederickson et al., 1992 (Frederickson et al., ,1994 Kirlin et al., 1989; Land et al., 1989) . Preliminary suggestions that these activities were related to NAT2 rather than NATl (Kirlin et al., 1989; Land et al., 1989) were not substantiated when a larger number of samples were analyzed (Frederickson et al., 1994) . It is clear from the latter study (Frederickson et al., 1994 ) that the enzyme involved was independent of the NATZ phenotype and had an activity profile consistent with that of NAT1.
Exfoliated bladder cells are commonly used in the surveillance of bladder cancer patients, as the method for obtaining them is convenient and noninvasive. The use of immunocytochemical markers such as Lewis X antigen, carcinoembryonic antigen, and epithelial membrane antigen to stain exfoliated bladder tumor cells provides important information concerning rates of tumor progression (Sagerman et al., 1994; Tanaka et al., 1994) . The detection of NATl in exfoliated cells from healthy individuals raises the possibility that exfoliated cells from cancer patients might be used to follow changes in NATl expression during tumor progression. To this end, studies are now in progress in which NATl expression is being analyzed in exfoliated cells collected from individuals with and without bladder tumors identified by flexible cytoscopy. The aim is to correlate any changes in NATl expression with tumor progression in these patients. To identify the stage of malignant progression at which such changes occur, the timing of such changes can be related to the expression of urothelial differentiation markers such as uroplakins Ia, Ib, 11, and 111 .
Tumor markers, along with NAT genotyping and indices of carcinogen exposure, have also been employed in "field molecular epidemiology" studies to screen workers in populations at risk from occupational bladder cancer (Bi et al., 1993) . Direct measurement of the N-acetylation rate in cells or biopsies would be necessary to quantitate metabolic capacity under these circumstances. When studies are to be performed "on site," however, it is clearly easier to obtain exfoliated cells and fix them for transportation and subsequent analysis than to preserve samples in a metabolically active state suitable for direct estimation of acetylation capacity. The use of immunochemical analysis of NATl expression in exfoliated cells could provide an estimate of the level of expression of this important carcinogen-metabolizing enzyme in the target organ.
The expression of NATl was also analyzed in normal pig bladder. An immunoreactive band was detected at approximately 31 KD in pig bladder homogenate, indicating that the pig expresses a form of NAT with the same C-terminal sequence as human NAT1. The presence in pig bladder of PABA-acetylating capacity was consistent with this finding. To our knowledge, this is the first report of N-acetylation and NAT expression in ovine tissue.
When neoplastic bladder cells were analyzed, immunoreactive NATl protein was detected in the human bladder tumor-derived cell lines EJ138 and RT112/84 and in the monocytic cell line U937. These cell lines have previously been shown to express NAT1dependent enzyme activities (Coroneos and Sim, 1991; Coroneos et al., 1991) , and NATl mRNA has been detected in U937 cells by RT-PCR .
In the present study we were unable to detect NAT2 protein by Western blot analysis in any of the bladder samples analyzed.
This finding was consistent with the absence of SMZ acetylating activity from pig bladder homogenate, and with previous studies on the bladder tumor-derived cell lines (Coroneos and Sim, 1991; Coroneos et al., 1991) . These data contradict a recent report (Kloth et al., 1994) that NAT2 can be detected by RT-PCR in cultured human urothelial cells. However, there are several possible explanations for the apparent discrepancy. The most likely one relates to the structure of the NAT2 gene, which lacks introns in the coding region (Ebisawa and Deguchi, 1991) . The primers used by Kloth et al. (1994) bind within the coding region, so that their results could be accounted for by the presence of small amounts of genomic DNA in their mRNA samples. Alternative explanations are that NATZ mRNA is expressed but not translated in human bladder epithelium, or that our immunochemical analysis was insufficiently sensitive to detect low levels of NAT2. Further work is in progress to improve the sensitivity of the Western blotting and immunocytochemical procedures to eliminate the third possibility.
The anti-peptide antiserum against the C-terminus of NATl (184) was used for immunocytochemical analysis of paraffinembedded human bladder tumors. In these samples, NATl was localized to those cells that retained some characteristics of welldifferentiated urothelial cells. The staining was particularly intense in the cells lining the bladder lumen, which closely resembled umbrella cells. To identlfy these cells unequivocally, future studies could profitably make use of available antisera to detect the urothelial differentiation markers uroplakin Ia and Ib, which are specific to terminally differentiated human and bovine umbrella cells Yu et al., 1994) .
The detection of NATl in well-differentiated bladder tumors is consistent with the hypothesis that NATl plays a role in the metabolism of carcinogens that reach the bladder epithelium via the urine. To relate the expression of NATl directly to the differentiation status of tumors, uroplakin expression may be valuable as a marker of urothelial differentiation. Uroplakin I1 has recently been cloned and sequenced and, interestingly, its 5' flanking region has been shown to contain a 3.5-KB sequence which directs gene expression to the suprabasal layers of the urothelium . It is not yet known whether all genes expressed in the urothelium contain such a regulatory region, but it would be of interest to discover whether the expression of NATl is directed by this or similar sequences.
The reduced level of NATl expression in more advanced regions of the tumors, where the cells were poorly differentiated, is intriguing in the light of studies indicating that the region of chromosome 8 on which the NATl gene is found may be deleted during bladder tumor progression (Knowles et al., 1993) . However, more detailed studies are required to assess the significance of this finding. To do this, it is necessary to examine a wider range of control samples, including normal human bladder (either biopsies or postmortem material) and to compare the expression profiles detected with those in a larger number of bladder tumors whose stage of progression is known. Further studies using resected superficial and invasive tumors and nonmalignant bladder tissue are now in progress.
At the earliest stages of bladder carcinogenesis, NAT may be important in protecting urothelial cells against mutagenic carcinogen metabolites that are released from glucuronide conjugates under acidic conditions (Kadlubar et al., 1991) . It is known that such metabolites are present in the urine of workers exposed to aromatic amines in the workplace (Sinues et al., 1992; Dewan et al., 1986) and in the urine of smokers (Hirvonen et al., 1994) . Even in the absence of industrial exposure, carcinogen-DNA adducts can be detected in exfoliated bladder epithelial cells after low-level environmental exposure (Vineis et al., 1994) . The capacity of NATl to detoxify aromatic amine metabolites (Hein et al., 1993; Minchin et al., 1992 ) may be very important in protecting the bladder against these compounds, although the caveat that NATl also has the capacity to activate carcinogens by 0-acetylation and N,Otransacetylation should be borne in mind. It is certainly the case that bladder epithelial cells can mediate 0-deacetylation and DNA binding of aromatic amines as well as their N-acetylation Swaminathan and Reznikoff, 1992) . The use of monospecific antisera such as those described herein, in addition to existing enzymatic methods, will help to resolve the remaining questions concerning the role of NATs in determining bladder cancer risk.
Recent genetic studies have also suggested a role for NATs in the later stages of bladder cancer. The use of microsatellite markers to study loss of heterozygosity in tumors has revealed a common region of deletion around 8~23.1-21.3 in advanced bladder tumors (Knowles et al., 1993) as well as a number of other tumor types (Cunningham et al., 1993; Emi et al., 1992) . This region coincides exactly with the localization of the NAT genes (Hickman et al., 1994) , raising the possibility that either NATl or 2 or a very closely linked gene acts as a tumor suppressor gene in the bladder. If this were the case, NAT expression could be a useful marker of tumor progression. The combination of immunochemical studies with cytogenetic studies using probes that are currently under development in our laboratory (Matas et al., 1995) could provide valuable information concerning both the clinical and the biological importance of NAT in bladder cancer.
An understanding of NAT expression in human bladder is important because NAT may be involved at all stages of bladder carcinogenesis. The potential role of NAT in detoxifying bladder carcinogens Kadlubar, 1994) points to a possible role in tumor initiation and promotion. Recent reports of loss of heterozygosity on chromosome 8p in late-stage bladder tumors also indicate possible involvement of NAT in the progression of such tumors to full-blown malignancy. The antisera described in this report will be invaluable in elucidating the role of NAT in all these processes.
